Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia.

Abstract

AIM To evaluate the safety and efficacy of combined pegylated interferon and ribavirin for the treatment of chronic hepatitis C (HCV) in patients with sickle cell anemia (SCA). METHODS Fifty-two patients with SCA and HCV were treated over a period of 7 years from June 2002 to July 2009. Their medical records were reviewed for: age at treatment, sex, body… (More)
DOI: 10.4254/wjh.v2.i5.180

Topics

  • Presentations referencing similar topics